8-KMaterial AgreementsRegulation FDExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Material Agreement (May 16, 2014)

Filed May 16, 2014For Securities:ABT

Summary

Abbott Laboratories announced on May 15, 2014, the entry into a material definitive agreement to acquire CFR Pharmaceuticals S.A. through its wholly-owned subsidiary, Abbott Investments Luxembourg S.à r.l. This strategic move involves a tender offer for outstanding shares and a subsequent purchase of a significant stake in a holding company, effectively acquiring 100% of CFR Pharmaceuticals. The transaction values CFR Pharmaceuticals' equity at approximately $2.9 billion, with a total enterprise value of roughly $3.3 billion, including net debt. This acquisition is a key step for Abbott, likely aimed at expanding its product portfolio and geographic reach, particularly in emerging markets where CFR Pharmaceuticals has a strong presence. Investors should monitor the closing conditions and potential integration progress.

Key Highlights

  • 1Abbott Laboratories, through a subsidiary, has entered into a definitive agreement to acquire CFR Pharmaceuticals S.A.
  • 2The acquisition is structured as a tender offer for all outstanding ordinary shares of CFR Pharmaceuticals, followed by a purchase of a controlling stake in a holding company.
  • 3The total equity valuation for CFR Pharmaceuticals is approximately $2.9 billion.
  • 4The total transaction value, including net debt, is approximately $3.3 billion.
  • 5The transaction is subject to customary closing conditions.
  • 6Abbott's subsidiary, Abbott Investments Luxembourg S.à r.l., is the entity making the offer and purchase.
  • 7The announcement was made via a press release filed as an exhibit to the 8-K.

Frequently Asked Questions

This 8-K filing is primarily to announce Abbott Laboratories' entry into a material definitive agreement to acquire CFR Pharmaceuticals S.A. It details the terms of the transaction, including the acquisition structure and valuation.

The acquisition values CFR Pharmaceuticals' equity at $2.9 billion and has a total enterprise value of approximately $3.3 billion. This represents a significant investment for Abbott, likely to enhance its product offerings and market presence, particularly in Latin America, where CFR Pharmaceuticals is strong.

The acquisition involves two main steps: first, Abbott will make a tender offer for all outstanding ordinary shares of CFR Pharmaceuticals. Second, Abbott will purchase a 100% ownership interest in a holding company that indirectly owns approximately 73% of CFR Pharmaceuticals' shares, at the same price as if those shares were tendered.

Yes, the consummation of the transactions contemplated by the Transaction Agreement is subject to customary conditions, which are typical for acquisitions of this nature.